About Tyra Biosciences, Inc.
https://www.tyra.bioTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
CEO
Todd Harris
Compensation Summary
(Year 2024)
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:917.27K
XSU.TO
Weight:0.03%
Shares:637.61K
IWM
Weight:0.03%
Shares:637.61K
Summary
Showing Top 3 of 85
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:12.2M
Value:$356.2M
BOXER CAPITAL, LLC
Shares:6.45M
Value:$188.29M
ALTA PARTNERS MANAGEMENT COMPANY, L.P.
Shares:4.08M
Value:$119.14M
Summary
Showing Top 3 of 124
About Tyra Biosciences, Inc.
https://www.tyra.bioTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $32.94M ▲ | $-29.87M ▼ | 0% | $-0.5 ▼ | $-29.74M ▲ |
| Q2-2025 | $0 | $31.45M ▼ | $-28.1M ▲ | 0% | $-0.47 | $-31.31M ▲ |
| Q1-2025 | $0 | $31.85M ▲ | $-28.15M ▼ | 0% | $-0.47 ▼ | $-31.71M ▼ |
| Q4-2024 | $0 | $29.74M ▲ | $-25.57M ▼ | 0% | $-0.43 ▼ | $-29.6M ▼ |
| Q3-2024 | $0 | $28.6M | $-24.02M | 0% | $-0.41 | $-28.48M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $274.92M ▼ | $301.85M ▼ | $21.34M ▲ | $280.51M ▼ |
| Q2-2025 | $296.27M ▼ | $321.5M ▼ | $19.35M ▼ | $302.15M ▼ |
| Q1-2025 | $318.94M ▼ | $343.48M ▼ | $19.94M ▼ | $323.53M ▼ |
| Q4-2024 | $341.44M ▼ | $363.56M ▼ | $20.41M ▲ | $343.15M ▼ |
| Q3-2024 | $360.13M | $380.59M | $18.3M | $362.29M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.87M ▼ | $-22.38M ▲ | $-14.81M ▼ | $647K ▲ | $-36.54M ▼ | $-22.42M ▲ |
| Q2-2025 | $-28.1M ▲ | $-23.68M ▲ | $20.87M ▼ | $583K ▼ | $-2.23M ▼ | $-23.71M ▲ |
| Q1-2025 | $-28.15M ▼ | $-25.46M ▼ | $32.03M ▲ | $2.19M ▲ | $8.76M ▲ | $-25.47M ▼ |
| Q4-2024 | $-25.57M ▼ | $-19.59M ▼ | $6.96M ▼ | $706K ▼ | $-11.93M ▼ | $-19.6M ▼ |
| Q3-2024 | $-24.02M | $-17.9M | $21.56M | $743K | $4.4M | $-17.95M |
CEO
Todd Harris
Compensation Summary
(Year 2024)
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:917.27K
XSU.TO
Weight:0.03%
Shares:637.61K
IWM
Weight:0.03%
Shares:637.61K
Summary
Showing Top 3 of 85
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:12.2M
Value:$356.2M
BOXER CAPITAL, LLC
Shares:6.45M
Value:$188.29M
ALTA PARTNERS MANAGEMENT COMPANY, L.P.
Shares:4.08M
Value:$119.14M
Summary
Showing Top 3 of 124